Search Results - "Tuttle, Jay"

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease by Sands, Bruce E., Peyrin-Biroulet, Laurent, Kierkus, Jaroslaw, Higgins, Peter D.R., Fischer, Monika, Jairath, Vipul, Hirai, Fumihito, D’Haens, Geert, Belin, Ruth M., Miller, Debra, Gomez-Valderas, Elisa, Naegeli, April N., Tuttle, Jay L., Pollack, Paul F., Sandborn, William J.

“…Mirikizumab is a humanized monoclonal antibody targeting interleukin 23p19 with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the…”
Get full text

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis by Sandborn, William J., Ferrante, Marc, Bhandari, Bal R., Berliba, Elina, Feagan, Brian G., Hibi, Toshifumi, Tuttle, Jay L., Klekotka, Paul, Friedrich, Stuart, Durante, Michael, Morgan-Cox, MaryAnn, Laskowski, Janelle, Schmitz, Jochen, D’Haens, Geert R.

“…Interleukin 23 contributes to the pathogenesis of ulcerative colitis (UC). We investigated the effects of mirikizumab, a monoclonal antibody against the p19…”
Get full text

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial by Cohen, Myron S, Nirula, Ajay, Mulligan, Mark J, Novak, Richard M, Marovich, Mary, Yen, Catherine, Stemer, Alexander, Mayer, Stockton M, Wohl, David, Brengle, Blair, Montague, Brian T, Frank, Ian, McCulloh, Russell J, Fichtenbaum, Carl J, Lipson, Brad, Gabra, Nashwa, Ramirez, Julio A, Thai, Christine, Chege, Wairimu, Gomez Lorenzo, Margarita M, Sista, Nirupama, Farrior, Jennifer, Clement, Meredith E, Brown, Elizabeth R, Custer, Kenneth L, Van Naarden, Jacob, Adams, Andrew C, Schade, Andrew E, Dabora, Matan C, Knorr, Jack, Price, Karen L, Sabo, Janelle, Tuttle, Jay L, Klekotka, Paul, Shen, Lei, Skovronsky, Daniel M

“…IMPORTANCE: Preventive interventions are needed to protect residents and staff of skilled nursing and assisted living facilities from COVID-19 during outbreaks…”
Get full text

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis by Sandborn, William J., Ferrante, Marc, Bhandari, Bal R., Berliba, Elina, Hibi, Toshifumi, D’Haens, Geert R., Tuttle, Jay L., Krueger, Kathryn, Friedrich, Stuart, Durante, Michael, Arora, Vipin, Naegeli, April N., Schmitz, Jochen, Feagan, Brian G.

“…Mirikizumab is an antibody against the p19 subunit of interleukin 23 that has demonstrated clinical efficacy and was well tolerated following 12 weeks of…”
Get full text

The anti-SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination by Benschop, Robert J, Tuttle, Jay L, Zhang, Lin, Poorbaugh, Josh, Kallewaard, Nicole L, Vaillancourt, Peter, Crisp, Melissa, Trinh, Thi Ngoc Vy, Freitas, Joshua J, Beasley, Stephanie, Daniels, Montanea, Haustrup, Natalie, Higgs, Richard E, Nirula, Ajay, Cohen, Myron S, Marovich, Mary

“…As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the…”
Get more information

A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia by Vadhan-Raj, Saroj, Abonour, Rafat, Goldman, Jonathan W, Smith, David A, Slapak, Christopher A, Ilaria, Jr, Robert L, Tiu, Ramon V, Wang, Xuejing, Callies, Sophie, Cox, Joanne, Tuttle, Jay L, Lau, Yiu-Keung, Roeland, Eric J

“…Hepcidin plays a central role in iron homeostasis and erythropoiesis. Neutralizing hepcidin with a monoclonal antibody (mAb) may prevent ferroportin…”
Get full text

Innovative clinical trial design and delivery: a phase 3 COVID-19 post-exposure prophylaxis study in skilled nursing and assisted living facilities (BLAZE-2) by Knorr, Jack, Tuttle, Jay L, Sabo, Janelle A, East, Dawn H, Price, Karen L, Shen, Lei

“…Abstract The efficient community spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the current pandemic of coronavirus…”
Get full text

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study by Steere, Boyd, Schmitz, Jochen, Powell, Nick, Higgs, Richard, Gottlieb, Klaus, Liu, Yushi, Jia, Bochao, Tuttle, Jay L., Sandborn, William J., Sands, Bruce E., D'Haens, Geert, Reinisch, Walter, Krishnan, Venkatesh

“…Mirikizumab, a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, demonstrated efficacy and was well-tolerated in a phase 2 randomized…”
Get full text

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis by Dubinsky, Marla C, Jairath, Vipul, Feagan, Brian G, Naegeli, April N, Tuttle, Jay, Morris, Nathan, Shan, Mingyang, Arora, Vipin, Lissoos, Trevor, Agada, Noah, Hibi, Toshifumi, Sands, Bruce E

“…ObjectiveMirikizumab, a monoclonal antibody targeting the interleukin-23 p19 subunit, was effective in a Phase 2 study (NCT02589665) of moderately-to-severely…”
Get full text

Shear level influences resistance artery remodeling: wall dimensions, cell density, and eNOS expression by Tuttle, J L, Nachreiner, R D, Bhuller, A S, Condict, K W, Connors, B A, Herring, B P, Dalsing, M C, Unthank, J L

“…The magnitude of shear stimulus has been shown to determine the level of growth factor expression in cell culture. However, little is known regarding what…”
Get more information

Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis. Reply by Tuttle, Jay, Emery, Paul, Nirula, Ajay

Get full text

Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis by Nepal, Desh, Putman, Michael, Tuttle, Jay, Emery, Paul, Nirula, Ajay

“…To the Editor: Inhibition of programmed cell death protein 1 (PD-1), which restores the ability of cytotoxic T cells to target and eliminate malignant cells,…”
Get full text

Impaired collateral development in mature rats by Tuttle, Jay L, Hahn, Tara L, Sanders, Bridget M, Witzmann, Frank A, Miller, Steven J, Dalsing, Michael C, Unthank, Joseph L

“…The effect of maturation on collateral development of resistance arteries was investigated. Three to four sequential mesenteric arteries were ligated to create…”
Get more information

A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis by Tuttle, Jay, Drescher, Edit, Simón-Campos, Jesus Abraham, Emery, Paul, Greenwald, Maria, Kivitz, Alan, Rha, Hyungmin, Yachi, Pia, Kiley, Christina, Nirula, Ajay

“…In this phase 2 placebo-controlled trial, peresolimab, a humanized monoclonal antibody that stimulates the programmed cell death protein 1 inhibitory pathway,…”
Get full text

Impaired Collateral Artery Development in Spontaneously Hypertensive Rats by TUTTLE, JAY L., SANDERS, BRIDGET M., BURKHART, HAROLD M., FATH, STEVEN W., KERR, KIMBERLY A., WATSON, WILLIAM C., HERRING, B. PAUL, DALSING, MICHAEL C., UNTHANK, JOSEPH L.

“…ABSTRACT Objective: To determine whether collateral artery development is impaired in spontaneously hypertensive (SHR) relative to normotensive (WKY) rats…”
Get full text

Fr543 MIRIKIZUMAB INDUCES REDUCTION OF IL-23 RELATED CYTOKINES IL-17A AND IL-23 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE by Schmitz, Jochen, Higgs, Richard, Ho, Stephen, Sissons, Sean, Tuttle, Jay, Pollack, Paul, Fischer, Monika, Hindryckx, Pieter

Get full text

P067 IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A PHASE 2 STUDY ANALYSIS USING THE SF-36 V2 STANDARD by Lichtenstein, Gary, Feagan, Brian, Tuttle, Jay, Morris, Nathan, Dong, Yan, Arora, Vipin, Naegeli, April, Rubin, David

Get full text

P067 IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A PHASE 2 STUDY ANALYSIS USING THE SF-36 V2 STANDARD by Lichtenstein, Gary, Feagan, Brian, Tuttle, Jay, Morris, Nathan, Dong, Yan, Arora, Vipin, Naegeli, April, Rubin, David

“…Abstract Background Mirikizumab (LY3074828) is a humanized monoclonal antibody directed against the p19 subunit of IL-23, and had demonstrated efficacy in…”
Get full text

Tu1887 IMPACT OF MIRIKIZUMAB TREATMENT ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ULCERATIVE COLITIS: A PHASE 2 STUDY ANALYSIS USING THE SF-36 V2 STANDARD by Lichtenstein, Gary R., Feagan, Brian G., Tuttle, Jay, Morris, Nathan, Dong, Yan, Arora, Vipin, Naegeli, April N., Rubin, David T.

Get full text

Sa1125 GENE EXPRESSION (GE) VALUES IN A PHASE 2 TRIAL OF MIRIKIZUMAB IN ULCERATIVE COLITIS (UC) CORRELATE BETTER WITH HISTOPATHOLOGY (HP) THAN ENDOSCOPY (EN) AND MAYO SCORES by Steere, Boyd, Gottlieb, Klaus, Schmitz, Jochen, Higgs, Richard, Jia, Bochao, Milch, Catherine, Tuttle, Jay, Krishnan, Venkatesh, Belin, Ruth, Reinisch, Walter

Get full text